Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valerio TherapeuticsXPAR:ALVIO -3.13%26 Equity-to-Asset is 0.14 as of Dec. 2025, which is 75% below its 10-year median of 0.57. GuruFocus rates XPAR:ALVIO with a GF Score™ of 26/100 and a GF Value™ of €0.07 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Valerio Therapeutics ranks worse than 83.99% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Valerio Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was €2.08 Mil. Valerio Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was €15.23 Mil.
Therefore, Valerio Therapeutics's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.14.
The historical rank and industry rank for Valerio Therapeutics's Equity-to-Asset or its related term are showing as below:
XPAR:ALVIO'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.5 Med: 0.57 Max: 0.75
Current: 0.14
During the past 13 years, the highest Equity to Asset Ratio of Valerio Therapeutics was 0.75. The lowest was -0.50. And the median was 0.57.
XPAR:ALVIO's Equity-to-Asset is ranked worse than 83.99% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs XPAR:ALVIO: 0.14
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Valerio Therapeutics Equity-to-Asset Related Terms
Valerio Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALVIO vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Valerio Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Valerio Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (XPAR:ALVIO) has a Equity-to-Asset of 0.14 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valerio Therapeutics and its competitors. This is 75% below median its historical median of 0.57. According to the industry distribution chart, Valerio Therapeutics ranks #1186 out of 1412 companies in the Biotechnology industry, placing it in the top 84%.
Is Valerio Therapeutics' Equity-to-Asset too high?
Valerio Therapeutics' current Equity-to-Asset of 0.14 is 75% below median its 10-year median of 0.57. The Biotechnology industry median Equity-to-Asset is 0.69. Valerio Therapeutics' value of 0.14 is 79.7% below this industry median. Based on the distribution chart, Valerio Therapeutics ranks #1186 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #1186 out of 1412 companies for Equity-to-Asset. This places Valerio Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.69. Valerio Therapeutics' value of 0.14 is 79.7% below this benchmark. While the company's 10-year median is 0.57 vs. the industry median of 0.69, Valerio Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valerio Therapeutics's current Equity-to-Asset of 0.14 is 79.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Valerio Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valerio Therapeutics's current Equity-to-Asset is 0.14, which is 75% below median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (XPAR:ALVIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.65 — trading 827.1% above its estimated fair value. The current Equity-to-Asset is 0.14, which is 75% below median its 10-year median of 0.57 and 79.7% below the Biotechnology industry median of 0.69. Valerio Therapeutics' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Valerio Therapeutics (XPAR:ALVIO), the current Equity-to-Asset is 0.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (XPAR:ALVIO) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.65 is trading 827.1% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for XPAR:ALVIO:
Equity-to-Asset: 0.14 (75% below median its 10-year median of 0.57)
GF Value™: €0.07 vs. price of €0.65 (827.1% above fair value)
Industry Position: 79.7% below the Biotechnology median (#1186 of 1412)
No single metric tells the full story. See the XPAR:ALVIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
26GF Score
Get the complete analysis for XPAR:ALVIO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVIO has been successfully added to your 
